All In Biotech

Drug Trial Radar · NCT06214052

VH4524184 Proof-of-Concept in Treatment-Naïve Adults Living With HIV-1

A Phase 2a, Randomized, Double-Blind (Sponsor Unblinded), Placebo-Controlled, Study to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of VH4524184 in HIV-1 Infected Treatment Naïve Adults

Last checked: Nov 20, 2026Latest source record: Jun 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

22

Actual

Start

Feb 7, 2024

Primary completion

Jun 12, 2024

Study completion Jun 12, 2024

Sponsor

Lead sponsor
ViiV HealthcareGSK (GSK)
Sponsor type
Industry
Collaborators
GlaxoSmithKline
First posted
Jan 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, ability of VH4524184 when given alone to reduce the amount of HIV (viral load) in people with HIV-1 infection who have never received antiretroviral therapy (treatment-naïve). Data from this study will be used to decide how VH4524184 can be best included in a full-treatment regimen for HIV-1 in the future.

Conditions

  • HIV Infections

Interventions

  • VH4524184Drug

    VH4524184 was administered as tablets orally at Day 1.

  • Matching PlaceboDrug

    VH4524184 Matching Placebo was administered as tablets orally at Day 1.

  • Antiretroviral therapyDrug

    Antiretroviral therapy was administered as available and as per investigator's recommendation.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Monotherapy: Maximum Change From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA)Time frame: At Day 10

Locations

17 sites in 5 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Bakersfield, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    West Hollywood, California

  • GSK Investigational Site

    DeLand, Florida

  • GSK Investigational Site

    Orlando, Florida

  • GSK Investigational Site

    Buenos Aires, Argentina

  • GSK Investigational Site

    Buenos Aires, Argentina

  • GSK Investigational Site

    Ciudad Autonoma de Bueno, Argentina

  • GSK Investigational Site

    Montreal, Quebec, Canada

  • GSK Investigational Site

    Québec, Quebec, Canada

  • GSK Investigational Site

    Milan, Italy

  • GSK Investigational Site

    Barcelona, Spain

  • GSK Investigational Site

    Barcelona, Spain

  • GSK Investigational Site

    Elche Alicante, Spain

  • GSK Investigational Site

    Madrid, Spain

  • GSK Investigational Site

    Murcia, Spain

  • GSK Investigational Site

    Valencia, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.